Improving study design for antidepressant effectiveness assessment

International Journal of Methods in Psychiatric Research

Volumn 22, Issue 3, 2013, Pages 217-231

  Naudet, Florian ^a,b,c   Millet, Bruno ^c,d   Reymann, Jean Michel ^c,e   Falissard, Bruno ^a,f,g  

^a Universite Paris Sud   (France)

^b Behavior and Basal Ganglia Unit EA 4712 University of Rennes 1   (France)

^c PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^d RENNES UNIVERSITY HOSPITAL   (France)

^e Inst de Rech Contre le Cancer IRCC   (France)

^f UNIVERSITÉ PARIS SACLAY   (France)

^g HÔPITAL PAUL BROUSSE   (France)

Author keywords

Antidepressants; Clinical trials; Depression; Effectiveness; Methodology

Indexed keywords

ANTIDEPRESSANT AGENT;

DEPRESSIVE DISORDER, MAJOR; DOUBLE BLIND PROCEDURE; HUMAN; METHODOLOGY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PERSONALITY ASSESSMENT; PSYCHOLOGY; PSYCHOMETRY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; STATISTICS AND NUMERICAL DATA;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; HUMANS; OBSERVATIONAL STUDY AS TOPIC; OUTCOME ASSESSMENT (HEALTH CARE); PERSONALITY ASSESSMENT; PSYCHOMETRICS; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN;

EID: 84884700948     PISSN: 10498931     EISSN: 15570657     Source Type: Journal    
DOI: 10.1002/mpr.1391     Document Type: Article

References (112)

1. Antonuccio D.O., Danton W.G., DeNelsky G.Y., Greenberg R.P., Gordon J.S. (1999) Raising questions about antidepressants. Psychotherapy and Psychosomatics, 68, 3-14.
2. Araya R. (1999) The management of depression in primary health care. Current Opinion in Psychiatry, 12, 103-107.
3. Arroll B., Elley C.R., Fishman T., Goodyear-Smith F.A., Kenealy T., Blashki G., Kerse N., Macgillivray S. (2009) Antidepressants versus Placebo for Depression in Primary Care, Cochrane Database System Review, CD007954, Chichester, John Wiley & Sons.
4. Bagby R.M., Ryder A.G., Schuller D.R., Marshall M.B. (2004) The Hamilton Depression Rating Scale: has the gold standard become a lead weight? American Journal of Psychiatry, 161, 2163-2177.
5. Bandelow B., Baldwin D.S., Dolberg O.T., Andersen H.F., Stein D.J. (2006) What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? Journal of Clinical Psychiatry, 67, 1428-1434.
6. Beauchamp T.L., Childress J.F. (2008) Principles of Biomedical Ethics, New York, Oxford University Press.
7. Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J. (1961) An inventory for measuring depression. Archives of General Psychiatry, 4, 561-571.
8. Benedetti F., Mayberg H.S., Wager T.D., Stohler C.S., Zubieta J.K. (2005) Neurobiological mechanisms of the placebo effect. Journal of Neuroscience, 25, 10390-10402.
9. Bluhm R. (2009) Some observations on observational research. Perspectives in Biology and Medicine, 52, 252-263.
10. Bombardier C., Maetzel A. (1999) Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies? Annals of the Rheumatic Diseases, 58(Suppl 1), I82-I85.
11. Bortolotti L., Mameli M. (2006) Deception in psychology: moral costs and benefits of unsought self-knowledge. Accountability in Research, 13, 259-275.
12. Brewin C.R., Bradley C. (1989) Patient preferences and randomised clinical trials. British Medical Journal, 299, 313-315.
13. Brownell K.D., Stunkard A.J. (1982) The double-blind in danger: untoward consequences of informed consent. American Journal of Psychiatry, 139, 1487-1489.
14. Brugha T.S., Bebbington P.E., MacCarthy B., Sturt E., Wykes T. (1992) Antidepressants may not assist recovery in practice: a naturalistic prospective survey. Acta Psychiatrica Scandinavica, 86, 5-11.
15. Bystritsky A., Waikar S.V. (1994) Inert placebo versus active medication. Patient blindability in clinical pharmacological trials. Journal of Nervous and Mental Disease, 182, 485-487.
16. Chilvers C., Dewey M., Fielding K., Gretton V., Miller P., Palmer B., Weller D., Churchill R., Williams I., Bedi N., Duggan C., Lee A., Harrison G. (2001) Antidepressant drugs and generic counselling for treatment of major depression in primary care: randomised trial with patient preference arms. British Medical Journal, 322, 772-775.
17. Colloca L., Lopiano L., Lanotte M., Benedetti F. (2004) Overt versus covert treatment for pain, anxiety, and Parkinson's disease. Lancet Neurology, 3, 679-684.
18. Concato J., Horwitz R.I. (2004) Beyond randomised versus observational studies. Lancet, 363, 1660-1661.
19. Dowrick C.F., Hughes J.G., Hiscock J.J., Wigglesworth M., Walley T.J. (2007) Considering the case for an antidepressant drug trial involving temporary deception: a qualitative enquiry of potential participants. BMC Health Services Research, 7, 64.
20. Dumville J.C., Torgerson D.J., Hewitt C.E. (2006) Reporting attrition in randomised controlled trials. British Medical Journal, 332, 969-971.
21. Duru G., Fantino B. (2008) The clinical relevance of changes in the Montgomery-Asberg Depression Rating Scale using the minimum clinically important difference approach. Current Medical Research Opinion, 24, 1329-1335.
22. Egger M., Smith G.D., Sterne J.A. (2001) Uses and abuses of meta-analysis. Clinical Medicine, 1, 478-484.
23. Enserink M. (1999) Can the placebo be the cure? Science, 284, 238-240.
24. Ernst E., Resch K.L. (1995) Concept of true and perceived placebo effects. British Medical Journal, 311, 551-553.
25. Even C., Siobud-Dorocant E., Dardennes R.M. (2000) Critical approach to antidepressant trials. Blindness protection is necessary, feasible and measurable. British Journal of Psychiatry, 177, 47-51.
26. Eyding D., Lelgemann M., Grouven U., Harter M., Kromp M., Kaiser T., Kerekes M.F., Gerken M., Wieseler B. (2010) Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. British Medical Journal, 341, c4737.
27. Falissard B., Lukasiewicz M., Corruble E. (2003) The MDP75: a new approach in the determination of the minimal clinically meaningful difference in a scale or a questionnaire. Journal of Clinical Epidemiology, 56, 618-621.
28. Falissard B., Milman D., Cohen D. (2013) A Generalization of the ≪Lady-Tasting-Tea≫ Procedure to Link Qualitative and Quantitative Approaches in Psychiatric Research International Journal of Statistics in Medical Research, 2, 88-93.
29. Fergusson D., Doucette S., Glass K.C., Shapiro S., Healy D., Hebert P., Hutton B. (2005) Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. British Medical Journal, 330, 396.
30. Finniss D.G., Kaptchuk T.J., Miller F., Benedetti F. (2010) Biological, clinical, and ethical advances of placebo effects. Lancet, 375, 686-695.
31. Fisher R.A. (1971) The Design of Experiments. Macmillan Pub Co; 9 edition (June 1971) .
32. Fournier J.C., DeRubeis R.J., Hollon S.D., Dimidjian S., Amsterdam J.D., Shelton R.C., Fawcett J. (2010) Antidepressant drug effects and depression severity: a patient-level meta-analysis. Journal of the American Medical Association, 303, 47-53.
33. Garcia-Toro M., Aguirre I. (2007) Biopsychosocial model in depression revisited. Medical Hypotheses, 68, 683-691.
34. Gaudiano B.A., Herbert J.D. (2005) Methodological issues in clinical trials of antidepressant medications: perspectives from psychotherapy outcome research. Psychotherapy and Psychosomatics, 74, 17-25.
35. Gemmell I., Dunn G. (2011) The statistical pitfalls of the partially randomized preference design in non-blinded trials of psychological interventions. International Journal of Methods in Psychiatric Research, 20, 1-9.
36. Gibbons R.D., Hur K., Brown C.H., Davis J.M., Mann J.J. (2012) Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Archives of General Psychiatry, 69(6), 572-579.
37. Greist J.H., Mundt J.C., Kobak K. (2002) Factors contributing to failed trials of new agents: can technology prevent some problems? Journal of Clinical Psychiatry, 63(Suppl 2), 8-13.
38. Guy W. (1976) ECDEU Assessment Manual for Psychopharmacology, Rockville, MD, US Department of Health, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration.
39. Hamilton M. (1960) A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry, 23, 56-62.
40. Howard L., Thornicroft G. (2006) Patient preference randomised controlled trials in mental health research. British Journal of Psychiatry, 188, 303-304.
41. Hrobjartsson A., Gotzsche P.C. (2010) Placebo Interventions for all Clinical Conditions, Cochrane Database System Review, CD003974, Chichester, John Wiley & Sons.
42. Huf W., Kalcher K., Pail G., Friedrich M.E., Filzmoser P., Kasper S. (2011) Meta-analysis: fact or fiction? How to interpret meta-analyses. World Journal of Biological Psychiatry, 12, 188-200.
43. Ioannidis J.P. (2008) Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials? Philosophy, Ethics, and Humanities in Medicine, 3, 14.
44. Judd L.L., Akiskal H.S., Maser J.D., Zeller P.J., Endicott J., Coryell W., Paulus M.P., Kunovac J.L., Leon A.C., Mueller T.I., Rice J.A., Keller M.B. (1998) Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. Journal of Affective Disorders, 50, 97-108.
45. Kadouri A., Corruble E., Falissard B. (2007) The improved Clinical Global Impression Scale (iCGI): development and validation in depression. BMC Psychiatry, 7, 7.
46. Katz T., Fisher P., Katz A., Davidson J., Feder G. (2005) The feasibility of a randomised, placebo-controlled clinical trial of homeopathic treatment of depression in general practice. Homeopathy, 94, 145-152.
47. Khan A., Leventhal R.M., Khan S.R., Brown W.A. (2002) Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. Journal of Clinical Psychopharmacology, 22, 40-45.
48. Khan A., Warner H.A., Brown W.A. (2000) Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Archives of General Psychiatry, 57, 311-317.
49. Kirsch I. (2000) Are drug and placebo effects in depression additive? Biological Psychiatry, 47, 733-735.
50. Kirsch I., Deacon B.J., Huedo-Medina T.B., Scoboria A., Moore T.J., Johnson B.T. (2008) Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Medicine, 5, e45.
51. Kirsch I., Moncrieff J. (2007) Clinical trials and the response rate illusion. Contemporary Clinical Trials, 28, 348-351.
52. Kirsch I., Sapirstein G. (1998) Listening to Prozac but hearing placebo: a meta-analysis of antidepressant medication. Prevention & Treatment 1.
53. Krell H.V., Leuchter A.F., Morgan M., Cook I.A., Abrams M. (2004) Subject expectations of treatment effectiveness and outcome of treatment with an experimental antidepressant. Journal of Clinical Psychiatry, 65, 1174-1179.
54. Lacasse J.R., Leo J. (2005) Serotonin and depression: a disconnect between the advertisements and the scientific literature. PLoS Medicine, 2, e392.
55. Lakoff A. (2002) The mousetrap: managing the placebo effect in antidepressant trials. Molecular Interventions, 2, 72-76.
56. Lavori P.W. (1992) Clinical trials in psychiatry: should protocol deviation censor patient data? Neuropsychopharmacology, 6, 39-48; discussion 9-63.
57. Lawlor D.A., Davey S.G., Bruckdorfer K.R., Kundu D., Ebrahim S. (2004) Observational versus randomised trial evidence. Lancet, 364, 755.
58. Leon A.C., Mallinckrodt C.H., Chuang-Stein C., Archibald D.G., Archer G.E., Chartier K. (2006) Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry, 59, 1001-1005.
59. Lewin S., Glenton C., Oxman A.D. (2009) Use of qualitative methods alongside randomised controlled trials of complex healthcare interventions: methodological study. British Medical Journal, 339, b3496.
60. Lexchin J., Bero L.A., Djulbegovic B., Clark O. (2003) Pharmaceutical industry sponsorship and research outcome and quality: systematic review. British Medical Journal, 326, 1167-1170.
61. Linde K., Schumann I., Meissner K., Jamil S., Kriston L., Rucker G., Antes G., Schneider A. (2011) Treatment of depressive disorders in primary care - protocol of a multiple treatment systematic review of randomized controlled trials. BMC Family Practice, 12, 127.
62. Little R.J.A., Rubin D.B. (eds) (1987) Statistical Analysis with Missing Data, New York, John Wiley & Sons.
63. Lynch F.L., Dickerson J.F., Clarke G., Vitiello B., Porta G., Wagner K.D., Emslie G., Asarnow J.R. Jr, Keller M.B., Birmaher B., Ryan N.D., Kennard B., Mayes T., DeBar L., McCracken J.T., Strober M., Suddath R.L., Spirito A., Onorato M., Zelazny J., Iyengar S., Brent D. (2011) Incremental cost-effectiveness of combined therapy vs medication only for youth with selective serotonin reuptake inhibitor-resistant depression: treatment of SSRI-resistant depression in adolescents trial findings. Archives of General Psychiatry, 68, 253-262.
64. Mathieu S., Boutron I., Moher D., Altman D.G., Ravaud P. (2009) Comparison of registered and published primary outcomes in randomized controlled trials. Journal of the American Medical Association, 302, 977-984.
65. M.R. Council (1948) Streptomycin treatment of pulmonary tuberculosis: a Medical Research Council investigation. British Medical Journal (Clinical Research Edition) 769-782.
66. Mertens T.E. (1993) Estimating the effects of misclassification. Lancet, 342, 418-421.
67. Moher D., Schulz K.F., Altman D.G. (2001) The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet, 357, 1191-1194.
68. Moncrieff J. (2002) The antidepressant debate. British Journal of Psychiatry, 180, 193-194.
69. Moncrieff J., Wessely S., Hardy R. (2004) Active Placebos versus Antidepressants for Depression, Cochrane Database System Review, CD003012, Chichester, John Wiley & Sons.
70. Montgomery S.A., Asberg M. (1979) A new depression scale designed to be sensitive to change. British Journal of Psychiatry, 134, 382-389.
71. Mundt J.C., Katzelnick D.J., Kennedy S.H., Eisfeld B.S., Bouffard B.B., Greist J.H. (2006) Validation of an IVRS version of the MADRS. Journal of Psychiatric Research, 40, 243-246.
72. Muthen B., Brown H.C. (2009) Estimating drug effects in the presence of placebo response: causal inference using growth mixture modeling. Statistics in Medicine, 28, 3363-3385.
73. N. Institute for Clinical Excellence (NICE) (ed.) (2010) The Treatment and Management of Depression in Adults (updated edition), National Clinical Practice Guideline 90, London, The British Psychological Society and The Royal College of Psychiatrists.
74. Naudet F., Maria A.S., Falissard B. (2011) antidepressant response in major depressive disorder: a meta-regression comparison of randomized controlled trials and observational studies. PLoS One, 6, e20811.
75. Noble L.M., Douglas B.C., Newman S.P. (2001) What do patients expect of psychiatric services? A systematic and critical review of empirical studies. Social Science and Medicine, 52, 985-998.
76. Olfson M., Marcus S.C., Druss B., Elinson L., Tanielian T., Pincus H.A. (2002) National trends in the outpatient treatment of depression. Journal of the American Medical Association, 287, 203-209.
77. Papakostas G.I., Fava M. (2009) Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. European Neuropsychopharmacology, 19, 34-40.
78. Perlis R.H., Ostacher M., Fava M., Nierenberg A.A., Sachs G.S., Rosenbaum J.F. (2010) Assuring that double-blind is blind. American Journal of Psychiatry, 167, 250-252.
79. Petkova E., Quitkin F.M., McGrath P.J., Stewart J.W., Klein D.F. (2000) A method to quantify rater bias in antidepressant trials. Neuropsychopharmacology, 22, 559-565.
80. Pilkington K., Kirkwood G., Rampes H., Fisher P., Richardson J. (2005) Homeopathy for depression: a systematic review of the research evidence. Homeopathy, 94, 153-163.
81. Posternak M.A., Solomon D.A., Leon A.C., Mueller T.I., Shea M.T., Endicott J., Keller M.B. (2006) The naturalistic course of unipolar major depression in the absence of somatic therapy. Journal of Nervous and Mental Disease, 194, 324-329.
82. Posternak M.A., Zimmerman M. (2000) Short-term spontaneous improvement rates in depressed outpatients. Journal of Nervous and Mental Disease, 188, 799-804.
83. Posternak M.A., Zimmerman M. (2007) Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trials: meta-analysis. British Journal of Psychiatry, 190, 287-292.
84. Posternak M.A., Zimmerman M., Keitner G.I., Miller I.W. (2002) A reevaluation of the exclusion criteria used in antidepressant efficacy trials. American Journal of Psychiatry, 159, 191-200.
85. Rabkin J.G., Markowitz J.S., Stewart J., McGrath P., Harrison W., Quitkin F.M., Klein D.F. (1986) How blind is blind? Assessment of patient and doctor medication guesses in a placebo-controlled trial of imipramine and phenelzine. Psychiatry Research, 19, 75-86.
86. Rihmer Z., Gonda X. (2008) Is drug-placebo difference in short-term antidepressant drug trials on unipolar major depression much greater than previously believed? Journal of Affective Disorders, 108, 195-198.
87. Ronalds C., Creed F., Stone K., Webb S., Tomenson B. (1997) Outcome of anxiety and depressive disorders in primary care. British Journal of Psychiatry, 171, 427-433.
88. Rutherford B., Sneed J., Devanand D., Eisenstadt R., Roose S. (2010) Antidepressant study design affects patient expectancy: a pilot study. Psychological Medicine, 40, 781-788.
89. Rutherford B.R., Sneed J.R., Roose S.P. (2009) Does study design influence outcome? The effects of placebo control and treatment duration in antidepressant trials. Psychotherapy and Psychosomatics, 78, 172-181.
90. Schulz K.F., Altman D.G., Moher D. (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Medicine, 7, e1000251.
91. Schulz K.F., Grimes D.A. (2002) Allocation concealment in randomised trials: defending against deciphering. Lancet, 359, 614-618.
92. Seemuller F., Moller H.J., Obermeier M., Adli M., Bauer M., Kronmuller K., Holsboer F., Brieger P., Laux G., Bender W., Heuser I., Zeiler J., Gaebel W., Schennach-Wolff R., Henkel V., Riedel M. (2010) Do efficacy and effectiveness samples differ in antidepressant treatment outcome? An analysis of eligibility criteria in randomized controlled trials. Journal of Clinical Psychiatry, 71, 1425-1433.
93. Severus E., Seemuller F., Berger M., Dittmann S., Obermeier M., Pfennig A., Riedel M., Frangou S., Moller H.J., Bauer M. (2012) Mirroring everyday clinical practice in clinical trial design: a new concept to improve the external validity of randomized double-blind placebo-controlled trials in the pharmacological treatment of major depression. BMC Medicine, 10, 67.
94. Shang A., Huwiler-Muntener K., Nartey L., Juni P., Dorig S., Sterne J.A., Pewsner D., Egger M. (2005) Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy. Lancet, 366, 726-732.
95. Sinyor M., Levitt A.J., Cheung A.H., Schaffer A., Kiss A., Dowlati Y., Lanctot K.L. (2010) Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses. Journal of Clinical Psychiatry, 71, 270-279.
96. Sneed J.R., Rutherford B.R., Rindskopf D., Lane D.T., Sackeim H.A., Roose S.P. (2008) Design makes a difference: a meta-analysis of antidepressant response rates in placebo-controlled versus comparator trials in late-life depression. American Journnal of Geriatric Psychiatry, 16, 65-73.
97. Sotsky S.M., Glass D.R., Shea M.T., Pilkonis P.A., Collins J.F., Elkin I., Watkins J.T., Imber S.D., Leber W.R., Moyer J., et al. (1991) Patient predictors of response to psychotherapy and pharmacotherapy: findings in the NIMH Treatment of Depression Collaborative Research Program. American Journal of Psychiatry, 148, 997-1008.
98. Suh T., Gallo J.J. (1997) Symptom profiles of depression among general medical service users compared with specialty mental health service users. Psychological Medicine, 27, 1051-63.
99. Tedeschini E., Fava M., Goodness T.M., Papakostas G.I. (2010) Relationship between probability of receiving placebo and probability of prematurely discontinuing treatment in double-blind, randomized clinical trials for MDD: a meta-analysis. European Neuropsychopharmacology, 20, 562-567.
100. Turner E.H., Matthews A.M., Linardatos E., Tell R.A., Rosenthal R. (2008) Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine, 358, 252-260.
101. Uhlenhuth E.H., Park L.C. (1964) The influence of medication (Imipramine) and doctor in relieving depressed psychoneurotic outpatients. Journal of Psychiatric Research, 69, 101-122.
102. van der Lem R., van der Wee N.J., van Veen T., Zitman F.G. (2012) Efficacy versus effectiveness: a direct comparison of the outcome of treatment for mild to moderate depression in randomized controlled trials and daily practice. Psychotherapy and Psychosomatics, 81, 226-234.
103. Vandenbroucke J.P. (2004) When are observational studies as credible as randomised trials? Lancet, 363, 1728-1731.
104. Walsh B.T., Seidman S.N., Sysko R., Gould M. (2002) Placebo response in studies of major depression: variable, substantial, and growing. Journal of the American Medical Association, 287, 1840-1847.
105. Waring D.R. (2008) The antidepressant debate and the balanced placebo trial design: an ethical analysis. International Journal of Law and Psychiatry, 31, 453-462.
106. Weintraub W., Aronson H. (1963) Clinical judgment in psychopharmacological research. Journal of Neuropsychiatry, 4, 65-70.
107. Wendler D., Miller F.G. (2004) Deception in the pursuit of science. Archives of Internal Medicine, 164, 597-600.
108. Wisniewski S.R., Rush A.J., Nierenberg A.A., Gaynes B.N., Warden D., Luther J.F., McGrath P.J., Lavori P.W., Thase M.E., Fava M., Trivedi M.H. (2009) Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. American Journal of Psychiatry, 166, 599-607.
109. Zimmerman M., Chelminski I., Posternak M.A. (2005) Generalizability of antidepressant efficacy trials: differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trial. American Journal of Psychiatry, 162, 1370-1372.
110. Zimmerman M., Galione J. (2010) Psychiatrists' and nonpsychiatrist physicians' reported use of the DSM-IV criteria for major depressive disorder. Journal of Clinical Psychiatry, 71, 235-238.
111. Zimmerman M., Mattia J.I., Posternak M.A. (2002) Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? American Journal of Psychiatry, 159, 469-473.
112. Zimmerman M., McGlinchey J.B., Posternak M.A., Friedman M., Attiullah N., Boerescu D. (2006) How should remission from depression be defined? The depressed patient's perspective. American Journal of Psychiatry, 163, 148-150.